Autoimmune hepatitis in an Internal Medicine ward

Authors

  • Teresa Vaio Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Paulo Ferreira Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Arsénio Santos Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Adélia Simão Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Rui Perdigoto Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Rui Santos Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Armando Carvalho Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Armando Porto Serviço de Medicina III dos Hospitais da Universidade de Coimbra

Keywords:

autoimmune hepatitis, International Autoimmune Hepatitis Group scoring system, clinical outcome, treatment

Abstract

Introduction: Autoimmune Hepatitis (AIH) is a hepatocellular inflammation of unknown cause, characterised by the presence of
interface hepatitis on liver biopsy, and hypergammaglobulinaemia and autoantibodies in serum.
Objective: To characterise clinical, laboratory and histological features, as well as the outcome, of AIH.
Methods - Retrospective analysis of AIH cases admitted between 1987 and 2002 in an Internal Medicine Ward.
Results: Twenty nine patients (pts), with a mean age of 34.2 ±16.4 years and a male-to-female ratio 1:28. The onset was
fulminant in 6.9%, acute in 20.7% and insidious or chronic in
72.4%. Asthenia (65.6%), anorexia (48.3%), nausea and vomiting (48.3%), were the most common symptoms; 24.1% were
asymptomatic. Applying the scoring system of the International
Autoimmune Hepatitis Group, the diagnosis was definitive in 69%
and probable in 31%. HAI type I was diagnosed in 86.2%, 3.5%
were type II and in 10.3% none of the standard antibodies were
found. Two pts were positive for anti-VHC, 1 for HbsAg and 1 had
a recent history of hepatitis A. Initial therapy was prednisolone in
13 pts and prednisolone + azathioprine in 15. Complete response
was achieved in 39.3%, partial response in 7.1%, failure in 25%
and relapse in 28.6%. Four patients underwent liver transplantation. During a mean follow-up period of 69 months (range, 1 to
213 months), the mortality was 13.8%: 2 pts died from hepatic
failure, 1 from sepsis and 1 from herpetic meningitis.
Conclusions: At the time of diagnosis, 24.1% of the patients
were asymptomatic and 27.1% had cirrhosis; therapy with prednisolone and azathioprine was more effective than prednisolone
monotherapy; liver transplantation was required in 4 patients; the
evolution was favourable in the majority of cases.

Downloads

Download data is not yet available.

References

Czaja AJ. Handbook of liver diseases. 10 th Edition. London: Churchill Livingstone, 1998: 63-83.

Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999; 57: 49-68.

McFarlane, IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998; 42:599-602.

Krawitz EL. Autoimmune hepatitis. N Eng J Medicine 1996; 344:897-903.

Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-497.

Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.

Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.

Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002; 22: 339-351.

Johanet C, Dubel L, Chazouilléres O. Auto-anticorps en hepatologie. Pathologie Biologie 1999 ; 47 : 997-1005.

Czaja AJ, Kruger M, Santrach PJ et al. Genetic Distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997; 92: 2197-2200.

Krawitz EL. Can you recognize autoimmune hepatitis?. Postgraduate Medicine 1998; 104: 145-152.

Czaja AJ. Treatment of Autoimmune hepatitis. Semin Liver Dis 2002; 22: 365-377.

Omagari K, Kinoshita H, Kato Y et al. Clinical features of 89 patients with autoimmune hepatitis in Nagasaki Prefecture, Japan. J Gastroenterol 1999; 34: 221-226.

Kanzler S, Gerken G, Lohr H, et al. Duration of imunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34: 354-355.

Vento S, Guella L, Mirandola F et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995; 346:608-609.

Vento S, Gaforano T, Di PierriG et al. Identification of hepatitis A virus as trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337:1183-1187.

Rahaman SM,Chira P, Koff RS. Idiopathic autoimmune chronic hepatitis triggered by hepatitis A. Am J Gastroenterol 1994; 89: 106-108.

Huppertz HY, Treichel U, Gassel AM et al. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995; 23: 204-208.

Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Diagnosis Disease Science 1989; 34:1294-1297.

Mackie FD, Peakman M, Yun M et al. Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 1994; 106: 1672-1675

Additional Files

Published

2008-06-30

How to Cite

1.
Vaio T, Ferreira P, Santos A, Simão A, Perdigoto R, Santos R, Carvalho A, Porto A. Autoimmune hepatitis in an Internal Medicine ward. RPMI [Internet]. 2008 Jun. 30 [cited 2024 May 14];15(2):87-92. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1454

Issue

Section

Original Articles

Most read articles by the same author(s)

<< < 1 2 3 4